Nivolumab: all 1,113 studies that test it
Page 8 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.
- Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT04787991Phase 1
- Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesTerminatedNCT04785287Phase 1/2
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
- A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid CancersStatus unknownNCT04761744Phase 2
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT04759586Phase 3
- FL-101 in Surgically Resectable Non-Small Cell Lung CancerWithdrawnNCT04758949Phase 2
- A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2
- Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.CompletedNCT04749602Phase 2
- Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursActive, not recruitingNCT04735978Phase 1
- Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.Active, not recruitingNCT04730544Phase 2
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersActive, not recruitingNCT04729322Phase 2
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2
- Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
- Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCTerminatedNCT04659369Phase 1
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 1
- A Study of BMS-936558 With SBRT After Induction Chemotherapy in CholangiocarcinomaTerminatedNCT04648319Phase 2
- The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionCompletedNCT04638439Phase 1
- Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownNCT04620954Phase 1/2
- Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCCompletedNCT04611165Phase 2
- Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedNCT04610671Phase 1
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
- A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04603248Not applicable
- SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingNCT04599140Phase 1/2
- NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaTerminatedNCT04594811Phase 1
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaCompletedNCT04581382Early Phase 1
- Nivolumab+Ipilimumab+RT in MSS mCRCStatus unknownNCT04575922Phase 2
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaActive, not recruitingNCT04572451Phase 1
- Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell CarcinomasStatus unknownNCT04570683Early Phase 1
- New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 3
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
- A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLCStatus unknownNCT04521075Phase 1/2
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
- Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedNCT04495257Phase 1
- A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT04477343Phase 1
- Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorCompletedNCT04465643Phase 1
- Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1
- Temozolomide, Cisplatin, and Nivolumab in People With Colorectal CancerCompletedNCT04457284Phase 2
- EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingNCT04444921Phase 3
- Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
- Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1
- A Study of DF6002 Alone and in Combination With NivolumabCompletedNCT04423029Phase 1
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingNCT04420975Phase 1
- Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) InfectionStatus unknownNCT04413838Phase 2
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
- Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line ChemotherapyCompletedNCT04401774Phase 2
- Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerStatus unknownNCT04377048Phase 2
- Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
- Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1
- Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerActive, not recruitingNCT04361162Phase 2
- Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
- COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1Status unknownNCT04356508Phase 2
- Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.Status unknownNCT04343144Phase 2
- Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsActive, not recruitingNCT04336241Phase 1
- Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsActive, not recruitingNCT04323046Phase 1
- CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionActive, not recruitingNCT04322955Phase 2
- Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaCompletedNCT04310709Phase 2
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
- Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk MelanomaActive, not recruitingNCT04309409Phase 3
- Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological MalignanciesTerminatedNCT04305249Phase 1
- Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT04300140Phase 1/2
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsTerminatedNCT04278144Phase 1/2
- Intratumoral Microdosing of Motolimod in HNSCCTerminatedNCT04272333Early Phase 1
- Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerCompletedNCT04271384Phase 2
- Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedNCT04270864Phase 1
- Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade GliomaCompletedNCT04267146Phase 1/2
- Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line TreatmentCompletedNCT04263090Phase 1/2
- Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerCompletedNCT04263051Phase 2
- Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2
- COL Immunotherapy Before Radiochimio + IpilimumabCompletedNCT04256213Not applicable
- A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Status unknownNCT04250246Phase 2
- Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.CompletedNCT04247165Phase 1/2
- GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1
- P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaStatus unknownNCT04233840Phase 1/2
- Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.Active, not recruitingNCT04229459Phase 2
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
- Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.TerminatedNCT04212026Phase 2
- Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaCompletedNCT04200963Phase 1
- Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBMActive, not recruitingNCT04195139Phase 2
- Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1
- Nivolumab with Chemotherapy in Pleural Mesothelioma After SurgeryCompletedNCT04177953Phase 2
- Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerTerminatedNCT04173325Phase 1
- NGS as the First-line Treatment in Advanced Biliary Tract CancerCompletedNCT04172402Phase 2
- Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2
- Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2
- A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaActive, not recruitingNCT04162015Phase 1
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2
- Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2